GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » GRAIL Inc (STU:NL0) » Definitions » FCF Margin %

GRAIL (STU:NL0) FCF Margin % : -245.19% (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is GRAIL FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. GRAIL's Free Cash Flow for the three months ended in Dec. 2024 was €-89.6 Mil. GRAIL's Revenue for the three months ended in Dec. 2024 was €36.5 Mil. Therefore, GRAIL's FCF Margin % for the quarter that ended in Dec. 2024 was -245.19%.

As of today, GRAIL's current FCF Yield % is -51.92%.

The historical rank and industry rank for GRAIL's FCF Margin % or its related term are showing as below:

STU:NL0' s FCF Margin % Range Over the Past 10 Years
Min: -1051.61   Med: -653.76   Max: -461.81
Current: -461.81


During the past 5 years, the highest FCF Margin % of GRAIL was -461.81%. The lowest was -1051.61%. And the median was -653.76%.

STU:NL0's FCF Margin % is ranked worse than
92.42% of 211 companies
in the Medical Diagnostics & Research industry
Industry Median: -2.33 vs STU:NL0: -461.81


GRAIL FCF Margin % Historical Data

The historical data trend for GRAIL's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GRAIL FCF Margin % Chart

GRAIL Annual Data
Trend Dec18 Dec19 Dec22 Dec23 Dec24
FCF Margin %
- - -1,051.62 -653.77 -463.69

GRAIL Quarterly Data
Dec18 Dec19 Jun20 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -437.88 -785.29 -541.71 -368.40 -245.19

Competitive Comparison of GRAIL's FCF Margin %

For the Diagnostics & Research subindustry, GRAIL's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GRAIL's FCF Margin % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, GRAIL's FCF Margin % distribution charts can be found below:

* The bar in red indicates where GRAIL's FCF Margin % falls into.


;
;

GRAIL FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

GRAIL's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-556.158/119.943
=-463.69 %

GRAIL's FCF Margin for the quarter that ended in Dec. 2024 is calculated as

FCF Margin=Free Cash Flow (Q: Dec. 2024 )/Revenue (Q: Dec. 2024 )
=-89.572/36.531
=-245.19 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


GRAIL FCF Margin % Related Terms

Thank you for viewing the detailed overview of GRAIL's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


GRAIL Business Description

Traded in Other Exchanges
Address
1525 O’Brien Drive, Menlo Park, CA, USA, 94025
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.

GRAIL Headlines

No Headlines